Dermira To Present At Stifel 2016 Healthcare Conference

MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Stifel 2016 Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Wednesday, November 16, 2016, in New York City. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira's corporate website at www.dermira.com.

About Dermira

Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira's portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com. 

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website ( www.dermira.com) and LinkedIn page ( https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira's website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts:Media: Erica JeffersonSenior Director, Head of Corporate Communications650-421-7216erica.jefferson@dermira.comInvestors:Andrew GuggenhimeChief Operating Officer and Chief Financial Officer650.421.7200investors@dermira.comRobert H. Uhl Westwicke PartnersManaging Director858.356.5932robert.uhl@westwicke.com

If you liked this article you might like

5 Ways Allergan Can Keep Up Momentum

These 4 Stocks Are Poised for Breakout Profits

These 5 Stocks Are Primed for Breakouts

Dermira (DERM) Stock Slumps Despite Favorable Trial Results

Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled